Ebola vaccination expanded to Ituri Province in the eastern Democratic Republic of the Congo (DRC), where health authorities and international partners launched the BRAVO vaccination study in Bunia, according to the official report issued Saturday by Xinhua and the Africa Centers for Disease Control and Prevention (Africa CDC).
BRAVO Study Targets Frontline Workers Against Bundibugyo Virus
The newly launched BRAVO study aims to vaccinate roughly 20,000 frontline workers across Ituri and North Kivu provinces, which are the regions most heavily impacted by the ongoing outbreak, according to Medecins Sans Frontieres (MSF) and Congolese health authorities. Conducted in collaboration with the Africa CDC and other scientific partners, the trial plans to follow participants over a period of nine to 12 months. This timeline includes three months of active vaccination and at least six months of post-vaccination monitoring.
Researchers designed the study to evaluate whether the Ervebo vaccine can protect against the Bundibugyo virus. Ervebo was originally developed and licensed to target the Zaire virus rather than the specific strain currently driving the DRC outbreak. Whether the vaccine provides cross-protection against the Bundibugyo strain remains unestablished by scientific consensus, making the trial a critical step in generating field evidence.
Vaccine Allocation and Rollout Figures Across Provinces
The International Coordinating Group on Vaccine Provision approved an initial allocation of 70,000 doses of Ervebo for the DRC in August, according to the Africa CDC. Out of that total, 50,000 doses were designated for health and frontline workers, while 20,000 doses were set aside specifically for Phase 3 clinical evaluations like the BRAVO study. By mid-September, the DRC had received 16,520 doses of the vaccine.
Vaccination efforts officially began on August 27 under a protocol-governed program focused on individuals at high risk of exposure. Government epidemiological updates show that 3,771 people received the vaccine as of September 17. That total includes 3,063 vaccinations in Tshopo Province and 708 vaccinations in Bas-Uele Province, prior to the recent expansion into Ituri Province.
Did You Know?
The current health emergency in the DRC marks the largest and deadliest Ebola outbreak ever recorded in the country, and stands globally as the second-largest Ebola epidemic in history, trailing only the 2014-2016 West Africa epidemic.
Epidemiological Impact and Fatality Rates in the DRC
The DRC government declared the outbreak in May. Since then, the virus has exacted a heavy toll across the affected eastern provinces. According to the latest government figures, the country has registered 7,541 confirmed cases of the disease.
Out of those confirmed cases, 3,639 deaths have been reported, yielding an overall case fatality rate of 48.3 percent. On the recovery side, a total of 1,823 patients have successfully beaten the illness and been discharged. Beyond the BRAVO trial, authorities plan a separate Phase 3 trial utilizing a randomized ring-vaccination strategy to further test Ervebo’s effectiveness against the circulating strain.
Frequently Asked Questions
What is the primary goal of the BRAVO study in the DRC?
The BRAVO study aims to vaccinate about 20,000 frontline workers in Ituri and North Kivu provinces and follow them over time to assess whether the Ervebo vaccine offers protection against the Bundibugyo virus.
Which virus does the Ervebo vaccine target?
Ervebo was originally developed and licensed to fight the Zaire virus. Scientists are currently studying whether it offers cross-protection against the Bundibugyo virus driving the present outbreak.
How many total doses of Ervebo were approved for the DRC?
The International Coordinating Group on Vaccine Provision approved an initial allocation of 70,000 doses of Ervebo to the DRC in August, with thousands of doses arriving by mid-September.
What is the current case fatality rate of the outbreak?
According to the DRC government, the overall case fatality rate stands at 48.3 percent, stemming from 7,541 confirmed cases and 3,639 recorded deaths.
Get Involved: Stay informed on global health developments by subscribing to our newsletter or sharing this article with your professional network. Have questions about ongoing health trials in Central Africa? Leave a comment below to join the discussion.
Keep reading